✦ LIBER ✦

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

✍ Scribed by White, W. B.; Pratley, R.; Fleck, P.; Munsaka, M.; Hisada, M.; Wilson, C.; Menon, V.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

EXamination of CArdiovascular OutcoMes w

✍ William B. White; George L. Bakris; Richard M. Bergenstal; Christopher P. Cannon 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 225 KB

Clinical pharmacology of alogliptin, a d

✍ Christopher, Ronald; Karim, Aziz 📂 Article 📅 2009 🏛 Expert Reviews 🌐 English ⚖ 691 KB

Alogliptin: a new, highly selective dipe

✍ Pratley, Richard E 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 362 KB

Efficacy and safety of the dipeptidyl pe

✍ R. E. Pratley; M. S. Kipnes; P. R. Fleck; C. Wilson; Q. Mekki; Alogliptin Study 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

The dipeptidyl peptidase-4 inhibitor alo

✍ Fujii, Yuki; Abe, Masanori; Higuchi, Terumi; Mizuno, Mari; Suzuki, Hiroko; Matsu 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 379 KB

Dipeptyl peptidase – 4 inhibitors in typ

✍ Zarowitz, Barbara J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 165 KB